(1-methyl-piperidin-4-ylidene)-acetonitrile | 37123-91-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (1-methyl-piperidin-4-ylidene)-acetonitrile
• 英文别名: (1-methyl-[4]piperidyliden)-acetonitrile；(1-methylpiperid-4-ylidene)acetonitrile；2-(1-Methylpiperidin-4-ylidene)acetonitrile
• CAS: 37123-91-4
• 化学式: C₈H₁₂N₂
• 分子量: 136.197
• InChiKey: OSFHBAOQNCPDEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  27
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  (1-methyl-piperidin-4-ylidene)-acetonitrile 在 potassium carbonate 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 23.0h， 生成 2-[4-(Dimethylamino)-1-methylpiperidin-4-yl]acetonitrile
  参考文献：
  名称：

  新型受限二胺的合成；2-(1-Aminocycloalkan-1-YL)乙胺

  摘要：

  摘要 利用亚环己基乙酸乙酯2和亚环烷基乙腈7与胺的迈克尔加成反应制备了新型受限二胺2-(1-氨基环烷-1-基)乙胺1。在迈克尔加成中，酯 2 需要高反应温度并得到几种产物，而 7 反应平稳并以良好的产率得到 2-(1-氨基-1-环己基)乙腈 8 (NH3 85%, MeNH2 89% EtNH2 80%) 和容易转化为二胺 1。

  DOI：

  10.1080/00397919808005943
• 作为产物：
  描述：

  cyano-(1-methyl-piperidin-4-ylidene)-acetic acid ethyl ester 在 盐酸 作用下， 生成 (1-methyl-piperidin-4-ylidene)-acetonitrile
  参考文献：
  名称：

  Battersby et al., Journal of the Chemical Society, 1953, p. 2463,2467

  摘要：

  DOI：

文献信息

• INDOL-2-ONE DERIVATIVES DISUBSTITUTED IN THE 3-POSITION, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：BARONI Marco

  公开号：US20100210662A1

  公开（公告）日：2010-08-19

  The present invention relates to 3-disubstituted indol-2-one derivatives, to their preparation and to their therapeutic application.

  本发明涉及3-二取代吲哚-2-酮衍生物，它们的制备方法以及它们的药用应用。
• [EN] GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS<br/>[FR] CYANOÉTHYLPYRAZOLOPYRIDONES À SUBSTITUTION GÉMINALE UTILISÉES COMME INHIBITEURS DE LA JANUS KINASE
  申请人：MERCK SHARP & DOHME

  公开号：WO2014146491A1

  公开（公告）日：2014-09-25

  The instant invention provides compounds of Formula (I) which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

  这项即时发明提供了Formula (I)的化合物，这些化合物是JAK抑制剂，因此可用于治疗JAK介导的疾病，如类风湿关节炎、哮喘、慢性阻塞性肺病和癌症。
• Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof
  申请人：Sanofi-Aventis

  公开号：US08202871B2

  公开（公告）日：2012-06-19

  The present application discloses compounds of the formula: and pharmaceutical compositions containing same and their use for treating and preventing various pathologies, including obesity, appetite disorders, excess weight and diabetes.

  本申请公开了以下式子的化合物： 并且包含这些化合物的药物组合物，以及它们用于治疗和预防各种病理情况，包括肥胖症、食欲紊乱、超重和糖尿病。
• OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE
  申请人：Sivakumar Meenakshi

  公开号：US20130005771A1

  公开（公告）日：2013-01-03

  The present invention relates to oxadiazole compounds in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable prodrugs and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the oxadiazole compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the treatment of cancer, particularly chronic myeloid leukemia (CML). The present invention further provides a method of treatment of cancer by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.

  本发明涉及噁唑烷化合物及其所有立体异构体、互变异构体和所有比例的混合物，以及它们的药学上可接受的盐、药学上可接受的溶剂化合物、药学上可接受的前药和药学上可接受的多型体。本发明还涉及制造噁唑烷化合物的方法以及包含它们的制药组合物。所述化合物及其制药组合物在治疗癌症，特别是慢性髓细胞白血病（CML）方面有用。本发明还提供了一种通过向需要治疗的哺乳动物中投与所述化合物或其制药组合物的治疗有效量来治疗癌症的方法。
• Discovery and In Vivo Efficacy of Trace Amine-Associated Receptor 1 (TAAR1) Agonist 4-(2-Aminoethyl)-N-(3,5-dimethylphenyl)piperidine-1-carboxamide Hydrochloride (AP163) for the Treatment of Psychotic Disorders
  作者：Mikhail Krasavin、Anatoly A. Peshkov、Alexey Lukin、Kristina Komarova、Lyubov Vinogradova、Daria Smirnova、Evgeny V. Kanov、Savelii R. Kuvarzin、Ramilya Z. Murtazina、Evgeniya V. Efimova、Maxim Gureev、Kirill Onokhin、Konstantin Zakharov、Raul R. Gainetdinov

  DOI：10.3390/ijms231911579

  日期：——

  Starting from a screening hit, a set of analogs was synthesized based on a 4-(2-aminoethyl)piperidine core not associated previously with trace amine-associated receptor 1 (TAAR1) modulation in the literature. Several structure–activity relationship generalizations have been drawn from the observed data, some of which were corroborated by molecular modeling against the crystal structure of TAAR1. The four most active compounds (EC50 for TAAR1 agonistic activity ranging from 0.033 to 0.112 μM) were nominated for evaluation in vivo. The dopamine transporter knockout (DAT-KO) rat model of dopamine-dependent hyperlocomotion was used to evaluate compounds’ efficacy in vivo. Out of four compounds, only one compound (AP163) displayed a statistically significant and dose-dependent reduction in hyperlocomotion in DAT-KO rats. As such, compound AP163 represents a viable lead for further preclinical characterization as a potential novel treatment option for disorders associated with increased dopaminergic function, such as schizophrenia.

  从一个筛选命中的化合物开始，基于4-（2-氨基乙基）哌啶核心合成了一组类似物，这种核心之前在文献中并未与痕量胺相关受体1（TAAR1）调节联系起来。观察到的数据得出了几个结构-活性关系的概括，其中一些经过了与TAAR1晶体结构的分子建模验证。最活跃的四个化合物（TAAR1激动活性的EC50范围为0.033至0.112μM）被提名进行体内评价。使用多巴胺转运体敲除（DAT-KO）大鼠模型评估化合物在体内的功效。在四个化合物中，只有一种化合物（AP163）在DAT-KO大鼠中表现出统计学显著且剂量依赖性的减少运动亢进。因此，化合物AP163代表了一个可行的先导化合物，可以作为潜在的新型治疗选项，用于与增加多巴胺能功能有关的疾病，如精神分裂症的治疗。